CollPlant Biotechnologies (CLGN) Operating Expenses (2017 - 2026)

CollPlant Biotechnologies' Operating Expenses history runs 10 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• Quarterly Operating Expenses fell 18.29% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (down 21.54% YoY) and the FY2025 annual result came in at $13.0 million, down 19.34% from the prior year.
• Operating Expenses was $2.9 million for Q1 2026 at CollPlant Biotechnologies, down from $3.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $4.7 million in Q4 2022 and bottomed at $2.9 million in Q1 2026.
• A 5-year average of $3.9 million and a median of $3.9 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 39.49% — and 2025, when it decreased 23.02%.
• CollPlant Biotechnologies' Operating Expenses stood at $4.7 million in 2022, then decreased by 1.67% to $4.6 million in 2023, then retreated by 15.85% to $3.9 million in 2024, then fell by 21.93% to $3.0 million in 2025, then fell by 4.84% to $2.9 million in 2026.
• Business Quant data shows CLGN's Operating Expenses at $2.9 million in Q1 2026, $3.0 million in Q4 2025, and $3.3 million in Q3 2025.